Abbreviation |
Definition |
AMPs |
Antimicrobial peptides/proteins |
AMR |
Antimicrobial resistance |
Anti-PD-1 |
Anti – programmed cell death protein 1 |
ASD |
Autism-spectrum disorders |
EPS |
Exopolysaccharides |
EV |
Extracellular vesicle |
FDA |
Food and Drug Administration |
FFT |
Fecal filtrate transplantation |
FMT |
Fecal microbiota therapy |
FPRA |
False positive relative abundance |
GI |
Gastrointestinal |
HuMiX |
Human microbial co-culture model |
IBD |
Inflammatory bowel disease |
IBS |
Irritable bowel syndrome |
iHACS |
Intestinal Hemi-Anaerobic Co-culture System |
IMMSA |
Microbiome and Multi-Omics Standards Alliance |
LBPs |
Live biotherapeutic products |
mAb |
Monoclonal antibody |
MET |
Microbial Ecosystem Therapeutic |
MHC |
major histocompatibility complex |
MIMICS |
Mimetic Intestinal Host – Microbe Interaction Coculture System |
MS |
Mass spectrometry |
NGS |
Next-generation sequencing |
Phe |
Phenylalanine |
PKU |
Phenylketonuria |
PTMs |
Post-translational modifications |
rCDI |
Recurrent Clostridioides difficile infection |
SARS-CoV2 |
Severe acute respiratory syndrome coronavirus 2 |
SCFA |
Short-chain fatty acid |
SHIME |
Simulation of the human intestinal microbial ecosystem |
SIHUMIx |
Simplified human intestinal microbiota |
STING |
Stimulator of interferon gene |
TCR |
T cell receptor |
WHO |
World Health Organization |